Robotics' Momentum Continues

Recs

18

Panic 2008... Profit 2009!

Fool -- Now's the time to invest! David and Tom Gardner's new book reveals their strategy for million dollar wealth.

On Tuesday, MAKO Surgical announced that it had filed a registration statement with the SEC for a proposed IPO of its common stock. This offering should prove to be very intriguing. The medical device maker has designed a surgeon-interactive robotic system that assists orthopedic surgeons in carrying out more precise and less invasive osteoarthritic knee surgeries. The company has only been around since 2004, and its CEO, Dr. Maurice Ferre, recently received the 2007 Ernst & Young Entrepreneur of the Year award for emerging companies in Florida.

MAKO Surgical will join a small group of robotic stocks that have made some major waves in recent years. Rule Breakers pick Intuitive Surgical (Nasdaq: ISRG) which makes the da Vinci Surgical System, a robotic arm to assist surgeons with minimally invasive surgeries, is a 10-bagger since going public in mid-2000. Intuitive Surgical continues to impress -- it's up 11% in just the past couple of months.

Also in this group is Hansen Medical (Nasdaq: HNSN) and Stereotaxis (Nasdaq: STXS). Hansen Medical is up more than 100% since its IPO last November. In May, Hansen received FDA approval for two of its robotic systems, the Sensei Robotic Catheter System and the Artisan Control Catheter. Stereotaxis is up more than 60% since its own IPO in the summer of 2004. The race is starting to heat up between the two.

Intuitive Surgical and its counterparts have set the bar high, but MAKO is definitely an IPO that should be watched closely -- especially for Fools who have entered middle age and have been hobbled by the early onset of osteoarthritis.

"The most exciting development in my lifetime!" 15 years ago, Motley Fool founder David Gardner uncovered a secret that changed how he'd invest forever. It can make you money in up, down, and rollercoaster markets. To learn more, enter your email address now.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 25, 2007, at 1:33 PM, pvfund wrote:

    It should be made clear that while STXS has FDA approval for surgical procedures HNSN does not. HNSN is FDA approved only for mapping and not for any other procedure due to concerns about tissue rupture.

  • Report this Comment On September 28, 2007, at 10:53 AM, hnsnlover wrote:

    The MFool pieces have been suprficial and bias heavily toward HNSN. Take a look at the thread titled Deutche Bank/Alex Brown Report on the Yahoo board as of 9/27/07 before deciding which of STXS and HNSN you think will be victor in the race for control of the world's EP labs and arrythmia ablation work.

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 537224, ~/articles/articlehandler.aspx, 1/9/2009 6:09:46 AM

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Most Recommended

Jan 8 at 4:06 PM

Market Summary

DJIA 8,742.46 -27.24 -0.31%
S&P 500 909.73 +3.08 +0.34%
NASD 1,617.01 +17.95 +1.12%
Sponsored by:

Related Tickers

Intuitive Surgical, Inc.

CAPS Rating 4/5 Stars

$110.54

-7.34 (-6.23%)

Outperform3365

Underperform172

Rate This Stock